Would you continue adjuvant FOLFOX for a patient with stage III colon cancer and triple-vessel coronary artery disease who developed NSTEMI after the first cycle?

This is a challenging scenario where the patient has existing triple vessel CAD and developed NSTEMI after 1st cycle. We all agree that 5-FU based therapy is the backbone for adjuvant therapy of stage III colon cancers. There are no clear cut guidelines in this case and management is per expert reco...